Moderna Stock: Growth, Innovation and Future Potential
Moderna stock (NASDAQ: MRNA) is back in the spotlight as investors reassess the biotechnology company’s future beyond its original COVID-19 vaccine success. On August 19, 2026, Moderna shares surged dramatically after the company and Merck announced positive Phase 3 results for their personalized mRNA cancer vaccine, intismeran, in high-risk melanoma. The treatment met its primary…